Home » Stocks » BSGM

BioSig Technologies, Inc. (BSGM)

Stock Price: $4.70 USD 0.11 (2.40%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
After-hours: $4.75 +0.05 (1.06%) Jan 21, 6:59 PM
Market Cap 136.70M
Revenue (ttm) n/a
Net Income (ttm) -58.56M
Shares Out 29.75M
EPS (ttm) -2.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $4.70
Previous Close $4.59
Change ($) 0.11
Change (%) 2.40%
Day's Open 4.56
Day's Range 4.40 - 4.81
Day's Volume 189,669
52-Week Range 2.56 - 11.84

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by G...

GlobeNewsWire - 1 week ago

Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processi...

GlobeNewsWire - 1 week ago

Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, u...

GlobeNewsWire - 1 week ago

PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovatio...

GlobeNewsWire - 2 weeks ago

Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal pr...

GlobeNewsWire - 1 month ago

NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease NeuroClear is set to commence experiments aimed at developing therapies for autonom...

Benzinga - 1 month ago

BioSig Technologies, Inc. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to recent information published on WHO's 2019 Gl...

Benzinga - 1 month ago

BioSig Technologies Inc (NASDAQ: BSGM), a medical device company, announced Friday a commercial milestone with respect to its FDA-approved PURE EP Systems. What Happened: Westport, Connecticut...

GlobeNewsWire - 1 month ago

Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence

GlobeNewsWire - 1 month ago

Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal pr...

GlobeNewsWire - 1 month ago

Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020 Company's flagship product to be featured in live pa...

Seeking Alpha - 2 months ago

BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)

GlobeNewsWire - 2 months ago

Westport, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical sign...

GlobeNewsWire - 2 months ago

First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center

GlobeNewsWire - 2 months ago

Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical sign...

24/7 Wall Street - 2 months ago

BioSig Technologies Inc. (NASDAQ: BSGM) was absolutely crushed on Monday after the company announced that it would halt its midstage coronavirus study.

Market Watch - 2 months ago

Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 trea...

GlobeNewsWire - 2 months ago

Westport, CT, Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralC...

GlobeNewsWire - 3 months ago

Westport, CT, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring...

GlobeNewsWire - 3 months ago

Westport, CT, Sept. 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc.  (V...

GlobeNewsWire - 4 months ago

Westport, CT, Sept. 21, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...

GlobeNewsWire - 4 months ago

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis. Abstract concludes PURE EP™ System is abl...

GlobeNewsWire - 4 months ago

Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical ...

GlobeNewsWire - 4 months ago

Westport, CT, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Westport, CT, September 14, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company develo...

GlobeNewsWire - 4 months ago

Westport, CT, Sept. 09, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...

GlobeNewsWire - 4 months ago

Westport, CT, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal...

GlobeNewsWire - 4 months ago

Westport, CT, Aug. 25, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical si...

Seeking Alpha - 5 months ago

BioSig is two investment opportunities rolled into one. An early-stage electrophysiology play, and a late-stage COVID-19 vaccine candidate.

GlobeNewsWire - 5 months ago

Westport, CT, Aug. 06, 2020 (GLOBE NEWSWIRE) --

GlobeNewsWire - 5 months ago

Westport, CT, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today a...

GlobeNewsWire - 5 months ago

Patient cases are set to commence in August Patient cases are set to commence in August

GlobeNewsWire - 5 months ago

Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government Company moves forward with the qualification to bid for contacts, grants an...

GlobeNewsWire - 5 months ago

Westport, CT, July 30, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical s...

GlobeNewsWire - 5 months ago

Chairman and CEO Kenneth L. Londoner to provide an update on the commercial rollout of PURE EP(tm) System, clinical development of BioSig’s pharmaceutical subsidiary and conduct virtual one-on...

GlobeNewsWire - 6 months ago

Westport, CT, July 20, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announc...

GlobeNewsWire - 6 months ago

ViralClear Chief Medical Officer Dr. Jerry Zeldis to Speak on Panel Titled “Arresting the Viral Replication Cycle” at B Riley FBR’s Infectious Disease Summit ViralClear Chief Medical Officer D...

GlobeNewsWire - 6 months ago

Westport, CT, July 16, 2020 (GLOBE NEWSWIRE) -- Amended

Seeking Alpha - 6 months ago

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Other stocks mentioned: BCRX, BNTX, CYDY, EIGR, GILD, IMUX, PFE, REGN
GlobeNewsWire - 6 months ago

Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, Rochester, MN, Jacksonville, FL, and Scottsdale, AZ Adult patients hospitalized with COVID-19 are enrolled in Austin, TX, ...

GlobeNewsWire - 6 months ago

Registration would provide Company access to business with the federal government, including contract and grant opportunities Registration would provide Company access to business with the fed...

GlobeNewsWire - 6 months ago

Westport, CT, July 08, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced tha...

GlobeNewsWire - 6 months ago

Former President and CEO of the North American division of AstraZeneca Plc to join as Independent Director Former President and CEO of the North American division of AstraZeneca Plc to join as...

GlobeNewsWire - 6 months ago

Westport, CT, June 29, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc., toda...

The Motley Fool - 6 months ago

The company announced a common stock offering.

GlobeNewsWire - 6 months ago

Westport, CT, June 24, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) today announced that it has entered into definitive agreements with sever...

GlobeNewsWire - 6 months ago

Westport, CT, June 22, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc., today announced t...

GlobeNewsWire - 7 months ago

Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patien...

Seeking Alpha - 7 months ago

BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Phase II Human Trials for Broad-Spectrum Oral Anti-Viral for Treatment of COVID-19 (Transcript)

GlobeNewsWire - 7 months ago

Randomized, double-blind, placebo-controlled Phase II trial of merimepodib to be conducted in adults with COVID-19 who are hospitalized and require supplemental oxygen or are on non-invasive v...

GlobeNewsWire - 7 months ago

Company’s flagship biomedical signal processing platform highlighted in two scientific sessions presented by key opinion leaders from Mayo Clinic Company’s flagship biomedical signal processin...

About BSGM

BioSig Technologies, a medical device company, engages in developing and commercializing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. The company's proprietary product include precise uninterrupted real-time evaluation of electrograms electrophysiology system, a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electr... [Read more...]

Industry
Medical Devices
Founded
2009
CEO
Kenneth L. Londoner M.B.A., MBA
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
BSGM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for BSGM stock is "Buy" and the 12-month stock price forecast is 13.00.

Price Target
$13.00
Analyst Consensus: Buy